{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:46:44Z","timestamp":1787312804576,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd011572","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000}}],"reference-count":267,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011572.pub2","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T13:21:44Z","timestamp":1504876904000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis"],"prefix":"10.1002","volume":"2017","author":[{"given":"Vipul","family":"Jairath","sequence":"first","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"Robarts Clinical Trials; London ON Canada"},{"name":"University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GY","family":"Zou","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London ON Canada"},{"name":"University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E","family":"Parker","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki","family":"AlAmeel","sequence":"additional","affiliation":[{"name":"King Fahad Specialist Hospital-Dammam; Department of Medicine; P.O Box 15215 Dammam Saudi Arabia 31444"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Al Beshir","sequence":"additional","affiliation":[{"name":"King Fahad Specialist Hospital-Dammam; Department of Medicine; P.O Box 15215 Dammam Saudi Arabia 31444"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid A","family":"Almadi","sequence":"additional","affiliation":[{"name":"King Khalid University Hospital; Division of Gastroenterology; Riyadh Saudi Arabia"},{"name":"King Saud University; Riyadh Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Al-Taweel","sequence":"additional","affiliation":[{"name":"Mubarak Al-Kabeer Hospital; Jabriyah Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan SS","family":"Atkinson","sequence":"additional","affiliation":[{"name":"John Radcliffe Hospital; Gastroenterology Unit; Headley Way Oxford UK OX3 9DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Biswas","sequence":"additional","affiliation":[{"name":"Wellcome Trust Centre for Human Genetics; Translational Gastroenterology Unit; Roosevelt Drive Oxford UK OX3 7BN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chapman","sequence":"additional","affiliation":[{"name":"John Radcliffe Hospital; Translational Gastroenterology Unit; Headley Way Oxford UK OX3 9DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parambir S","family":"Dulai","sequence":"additional","affiliation":[{"name":"University of California San Diego; La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Glaire","sequence":"additional","affiliation":[{"name":"John Radcliffe Hospital; Oxford UK OX3 9DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl R","family":"Hoekman","sequence":"additional","affiliation":[{"name":"Academic Medical Center; Meibergdreef 9 Amsterdam Netherlands 1105 AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Koutsoumpas","sequence":"additional","affiliation":[{"name":"John Radcliffe Hospital; Gastroenterology Unit; Headley Way Oxford UK OX3 9DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Minas","sequence":"additional","affiliation":[{"name":"Wexham Park Hospital; Wexham Slough Berkshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud H","family":"Mosli","sequence":"additional","affiliation":[{"name":"King Abdulaziz University; King Abdulaziz University Hospital; Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Samaan","sequence":"additional","affiliation":[{"name":"Academic Medical Center; Meibergdreef 9 Amsterdam Netherlands 1105 AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"Robarts Clinical Trials; London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Travis","sequence":"additional","affiliation":[{"name":"University of Oxford; Translational Gastroenterology Unit, Nuffield Department of Medicine; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D'Haens","sequence":"additional","affiliation":[{"name":"Academic Medical Center; Meibergdreef 9 Amsterdam Netherlands 1105 AZ"},{"name":"Robarts Clinical Trials; Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"University of California San Diego; Division of Gastroenterology; La Jolla CA USA"},{"name":"Robarts Clinical Trials; San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"University of Western Ontario; Department of Medicine; London ON Canada"},{"name":"Robarts Clinical Trials; London ON Canada"},{"name":"University of Western Ontario; Department of Epidemiology and Biostatistics; London ON Canada"},{"name":"Robarts Clinical Trials; Cochrane IBD Group; 100 Dundas Street, Suite 200 London ON Canada N6A 5B6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"10.1002\/14651858.CD011572.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1093\/ecco-jcc\/jju027.676","article-title":"Twice-daily budesonide rectal foam induces complete mucosal healing in Japanese patients with mild to moderate ulcerative colitis: Results of multicenter, randomized, double-blind, placebo-controlled trial","volume":"9","author":"Aoyama","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1023\/A:1018874120749","article-title":"Controlled trial of 4-ASA in ulcerative colitis","volume":"42","author":"Beeken","year":"1997","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0003|cit3","first-page":"S140","article-title":"Methotrexate for corticosteroid-dependent ulcerative colitis: Results of a placebo randomized controlled trial","volume":"1","author":"Carbonnel","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/ecco-jcc\/jju027.023","article-title":"Methotrexate for corticosteroid-dependent ulcerative colitis: Results of a placebo randomized controlled trial","volume":"9","author":"Carbonnel","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","article-title":"Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a large proportion of patients with ulcerative colitis","volume":"150","author":"Carbonnel","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S1873-9946(14)60012-X","article-title":"Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe ulcerative colitis: A phase 2 randomized placebo-controlled study","volume":"8","author":"Danese","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","article-title":"Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"64","author":"Danese","year":"2014","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Deventer SJ Tami JA Wedel MK A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis Gut 2004 1646 51","DOI":"10.1136\/gut.2003.036160"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Deventer SJ Wedel MK Baker BF Xia S Chuang E Miner PB A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis Alimentary Pharmacology and Therapeutics 2006 1415 25","DOI":"10.1111\/j.1365-2036.2006.02910.x"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD011572.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"A874","DOI":"10.1016\/S0016-5085(00)85637-1","article-title":"An ascending dose trial of a humanised a4b7 antibody in ulcerative colitis","volume":"118","author":"Feagan","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"A874","DOI":"10.1016\/S0016-5085(00)85637-1","article-title":"An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC)","volume":"118","author":"Feagan","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"A170","DOI":"10.1136\/gutjnl-2012-302514b.235","article-title":"A randomised placebo-controlled double-blind study of Octasa 4.8 g\/day (800 mg tablets 5-ASA) for the induction of endoscopic remission in patients with active ulcerative colitis","volume":"61","author":"Feagan","year":"2012","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2013.03.025","article-title":"The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis","volume":"145","author":"Feagan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S1873-9946(14)60101-X","article-title":"Improvements in health-related quality of life in patients with ulcerative colitis treated with vedolizumab","volume":"8","author":"Feagan","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S609","DOI":"10.14309\/00000434-201210001-01522","article-title":"Vedolizumab maintenance therapy for ulcerative colitis: Results of gemini I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial","volume":"107","author":"Feagan","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/S1873-9946(14)60621-8","article-title":"Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders","volume":"8","author":"Feagan","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/S1873-9946(13)60534-6","article-title":"Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in GEMINI I, a randomised, placebo-controlled, double-blind, multi-centre trial","volume":"7","author":"Feagan","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00054725-201212001-00002","article-title":"Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo-controlled, double-blind, multicenter trial","volume":"18","author":"Feagan","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011572.pub2-BIB0020|cit20","first-page":"S590","article-title":"Health-related quality of life in patients with ulcerative colitis after treatment with vedolizumab: Results from the GEMINI 1 study","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Feagan BG Rutgeerts P Sands BE Hanauer S Colombel JF Sandborn WJ Vedolizumab as induction and maintenance therapy for ulcerative colitis New England Journal of Medicine 2013 699 710","DOI":"10.1056\/NEJMoa1215734"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011572.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/S0016-5085(12)60607-6","article-title":"Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial","volume":"142","author":"Feagan","year":"2012","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD011572.pub2-BIB0023|cit23","first-page":"S590","article-title":"Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/00054725-201212001-00062","article-title":"Efficacy of vedolizumab in ulcerative colitis by prior treatment failure in gemini i, a randomized, placebo-controlled, double-blind, multicenter trial","volume":"18","author":"Parikh","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/01.MIB.0000438818.81129.5b","article-title":"Pharmacokinetic\/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from GEMINI 1 and 2","volume":"19","author":"Rosario","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0026|cit26","first-page":"S270","article-title":"Exposure response relationship during vedolizumab induction therapy in adults with ulcerative colitis","volume":"8","author":"Rosario","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1873-9946(14)60083-0","article-title":"Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies","volume":"8","author":"Rosario","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/S1873-9946(13)60344-X","article-title":"Sustained therapeutic benefit of vedolizumab throughout 1 year in ulcerative colitis in GEMINI I, a randomized, placebo-controlled, double-blind, multicenter trial","volume":"7","author":"Sandborn","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"S503","DOI":"10.14309\/00000434-201310001-01676","article-title":"Reductions in corticosteroid use in patients with ulcerative colitis or crohn's disease treated with vedolizumab","volume":"108","author":"Sands","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Hanauer S Good LI Goodman MW Pizinger RJ Strum WB Lyss C Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis American Journal of Gastroenterology 2000 1749 54","DOI":"10.1111\/j.1572-0241.2000.02185.x"},{"issue":"7","key":"10.1002\/14651858.CD011572.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MCG.0000000000000319","article-title":"Low-dose Infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis","volume":"49","author":"Jiang","year":"2015","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0032|cit32","doi-asserted-by":"crossref","unstructured":"Kamm MA Sandborn WJ Gassull M Schreiber S Jackowski L Butler T Once-daily, high-concentration MMX mesalamine in active ulcerative colitis Gastroeneterology 2007 66 75","DOI":"10.1053\/j.gastro.2006.10.011"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Leiper K Martin K Ellis A Subramanian S Watson AJ Christmas SE Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis Gut 2011 1520 6","DOI":"10.1136\/gut.2010.225482"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/j.gastro.2007.12.012","article-title":"Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial","volume":"134","author":"Lewis","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Lichtenstein GR Kamm MA Boddu P Gubergrits N Lyne A Butler T Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis Clinical Gastroenterology and Hepatology 2007 95 102","DOI":"10.1016\/j.cgh.2006.10.025"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Lichtenstein GR Gordon GL Zakko S Murthy U Sedghi S Pruitt R Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial Alimentary Pharmacology and Therapeutics 2010 990 9","DOI":"10.1111\/j.1365-2036.2010.04438.x"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Marteau P Probert CS Lindgren S Gassul M Tan TG Dignass A Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study Gut 2005 960 5","DOI":"10.1136\/gut.2004.060103"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gutjnl-2012-303424","article-title":"Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study","volume":"63","author":"Mayer","year":"2014","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0039|cit39","first-page":"S","article-title":"Phase IIB, randomized, placebo-controlled evaluation of the efficacy and safety of induction therapy with eldelumab (anti-IP-10 antibody; BMS-936557) in patients with active ulcerative colitis","volume":"1","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0040|cit40","first-page":"S162","article-title":"Phase IIa, randomized, placebo-controlled evaluation of the efficacy and safety of induction therapy with eldelumab (anti-IP-10 antibody; BMS-936557) in patients with active crohn's disease","volume":"1","author":"Sandborn","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gut.52.9.1286","article-title":"Interferon beta-1a in ulcerative colitis: A placebo controlled, randomised, dose escalating study","volume":"52","author":"Nikolaus","year":"2003","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Ogata H Kato J Hirai F Hida N Matsui T Matsumoto T Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis Inflammatory Bowel Diseases 2012 803 8","DOI":"10.1002\/ibd.21853"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Oren R Arber N Odes S Moshkowitz M Keter D Pomeranz I Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial Gastroenterology 1996 1416 21","DOI":"10.1053\/gast.1996.v110.pm8613046"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Reinisch W Sandborn WJ Hommes DW D'Haens G Hanauer S Schreiber S Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 2011 780 7","DOI":"10.1136\/gut.2010.221127"},{"issue":"6","key":"10.1002\/14651858.CD011572.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/gutjnl-2014-308337","article-title":"Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study","volume":"64","author":"Reinisch","year":"2015","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.MIB.0000456697.14546.81","article-title":"Budesonide MMX 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-asas","volume":"20","author":"David","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/ecco-jcc\/jju027.011","article-title":"Budesonide MMX 9 mg for inducing remission in patients with Mild-to-Moderate ulcerative colitis not adequately controlled with oral 5-ASAs","volume":"9","author":"Rubin","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Rutgeerts P Sandborn WJ Feagan BG Reinisch W Olson A Johanns J Infliximab for induction and maintenance therapy for ulcerative colitis New England Journal of Medicine 2005 2462 76","DOI":"10.1056\/NEJMoa050516"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Rutgeerts P Sandborn WJ Feagan BG Reinisch W Olson A Johanns J Infliximab for induction and maintenance therapy for ulcerative colitis New England Journal of Medicine 2005 2462 76","DOI":"10.1056\/NEJMoa050516"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Rutgeerts PJ Fedorak RN Hommes DW Sturm A Baumgart DC Bressler B A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis Gut 2013 1122 30","DOI":"10.1136\/gutjnl-2011-301769"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Rutgeerts PJ Fedorak RN Hommes DW Sturm A Baumgart DC Bressler B A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis Gut 2013 1122 30","DOI":"10.1136\/gutjnl-2011-301769"},{"issue":"5","key":"10.1002\/14651858.CD011572.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.13291","article-title":"Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis","volume":"42","author":"Rutgeerts","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Sandborn WJ Tremaine WJ Schroeder KW Batts KP Lawson GM Steiner BL A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis Gastroenterology 1994 1429 35","DOI":"10.1016\/0016-5085(94)90394-8"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1046\/j.1365-2036.2003.01589.x","article-title":"Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial","volume":"17","author":"Sandborn","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/S1873-9946(13)60589-9","article-title":"Sustained efficacy in patients with ulcerative colitis treated with adalimumab: results from ULTRA 2","volume":"7","author":"Ghosh","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/S0016-5085(13)60801-X","article-title":"Exposure-efficacy relationship (ER) for adalimumab during induction phase of treatment of adult patients with moderate to severe ulcerative colitis","volume":"1","author":"Mostafa","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00054725-201112002-00008","article-title":"Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe ulcerative colitis","volume":"17","author":"Sandborn","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0060|cit60","first-page":"S565","article-title":"One-year response and remission rates in ulcerative colitis patients with week 8 response to adalimumab: subanalysis of ULTRA 2","volume":"1","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00054725-201212001-00054","article-title":"Reduced steroid usage in ulcerative colitis patients with week 8 response to adalimumab: subanalysis of ULTRA 2","volume":"18","author":"Assche","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"Sandborn WJ Travis S Moro L Jones R Gautille T Bagin R Once-daily budesonide MMX extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE i study Gastroenterology 2012 1218 26","DOI":"10.1053\/j.gastro.2012.08.003"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Sandborn WJ Colombel JF Sands BE Rutgeerts P Targan SR Panaccione R Abatacept for Crohn's disease and ulcerative colitis Gastroenterology 2012 62 9","DOI":"10.1053\/j.gastro.2012.04.010"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"S542","DOI":"10.14309\/00000434-201310001-01799","article-title":"Budesonide foam for inducing remission in active mild-to-moderate ulcerative proctitis or ulcerative proctosigmoiditis: Results of two randomized, placebo-controlled trials","volume":"108","author":"Sandborn","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/01.MIB.0000438827.13410.d7","article-title":"Efficacy and safety of budesonide foam for inducing remission in mildly to moderately active ulcerative proctitis or ulcerative proctosigmoiditis","volume":"19","author":"Sandborn","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0070|cit70","first-page":"1","article-title":"Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, Phase 2b study","volume":"E-pub ahead of","author":"Sandborn","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0071|cit71","first-page":"S","article-title":"Phase IIB, randomized, placebo-controlled evaluation of the efficacy and safety of induction therapy with eldelumab (anti-IP-10 antibody; BMS-936557) in patients with active ulcerative colitis","volume":"146 (5 Suppl 1)","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Sands BE Sandborn WJ Creed TJ Dayan CM Dhanda AD Assche GA Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis Gastroenterology 2012 356 64.e1","DOI":"10.1053\/j.gastro.2012.04.043"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(08)62311-2","article-title":"Balsalazide tablets 3.3 g twice daily improves signs and symptoms of mild-to-moderate ulcerative colitis","volume":"134","author":"Bosworth","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"Scherl EJ Pruitt R Gordon GL Lamet M Shaw A Huang S Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study American Journal of Gastroenterology 2009 1452 9","DOI":"10.1038\/ajg.2009.83"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Schreiber S Keshavarzian A Isaacs KL Schollenberger J Guzman JP Orlandi C A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis Gastroenterology 2007 76 86","DOI":"10.1053\/j.gastro.2006.11.029"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Schroeder KW Tremaine WJ Ilstrup DM Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study New England Journal of Medicine 1987 1625 9","DOI":"10.1056\/NEJM198712243172603"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Sninsky CA Cort DH Shanahan F Powers BJ Sessions JT Pruitt RE Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study Annals of Internal Medicine 1991 350 5","DOI":"10.7326\/0003-4819-115-5-350"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Steinhart AH Hiruki T Brzezinski A Baker JP Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial Alimentary Pharmacology and Therapeutics 1996 729 36","DOI":"10.1046\/j.1365-2036.1996.d01-509.x"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/0016-5085(87)90621-4","article-title":"5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis","volume":"92","author":"Sutherland","year":"1987","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0080|cit80","doi-asserted-by":"crossref","unstructured":"Sutherland LR Martin F 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada Digestive Diseases and Sciences 1987 64s 6s","DOI":"10.1007\/BF01312466"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Sutherland LR Robinson M Onstad G Peppercorn M Greenberger N Goodman M A double-blind, placebo controlled, multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis Canadian Journal of Gastroenterology 1990 463 7","DOI":"10.1155\/1990\/921345"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1093\/ecco-jcc\/jju027.702","article-title":"Infliximab therapy for Japanese patients with ulcerative colitis: Efficacy, safety, and association between serum infliximab levels and early response in a randomized, double-blind, placebo-controlled study","volume":"9","author":"Suzuki","year":"2015","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: Results from the randomised CORE II study","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Assche G Sandborn WJ Feagan BG Salzberg BA Silvers D Monroe PS Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial Gut 2006 1568 74","DOI":"10.1136\/gut.2005.089854"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"issue":"9940","key":"10.1002\/14651858.CD011572.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0088|cit88","doi-asserted-by":"crossref","unstructured":"Watanabe M Nishino H Sameshima Y Ota A Nakamura S Hibi T Randomised clinical trial: Evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - A placebo-controlled study Alimentary Pharmacology and Therapeutics 2013 264 73","DOI":"10.1111\/apt.12362"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0089|cit89","doi-asserted-by":"crossref","unstructured":"Williams CN Haber G Aquino JA Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories Digestive Diseases and Science 1987 71s 5s","DOI":"10.1007\/BF01312468"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0090|cit90","first-page":"AB294","article-title":"AJM300, an oral A4 integrin antagonist, for active ulcerative colitis: A multicenter, randomized, double-blind, placebo-controlled phase 2a study","volume":"1","author":"Watanabe","year":"2014","journal-title":"Gastrointestinal Endoscopy"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0091|cit91","first-page":"S","article-title":"AJM300, an oral alpha4 integrin antagonist, for active ulcerative colitis: A multicenter, randomized, double-blind, placebo-controlled phase 2A study","volume":"1","author":"Watanabe","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1053\/j.gastro.2015.08.044","article-title":"Safety and efficacy of AJM300, an oral antagonist of a4I integrin, in induction therapy for patients with active ulcerative colitis","volume":"149","author":"Yoshimura","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/gut.33.5.711","article-title":"Oral fluticasone propionate in active distal ulcerative colitis","volume":"33","author":"Angus","year":"1992","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2036.1999.00473.x","article-title":"Is maintenance therapy always necessary for patients with ulcerative colitis in remission?","volume":"13","author":"Ardizzone","year":"1999","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"9940","key":"10.1002\/14651858.CD011572.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0140-6736(14)60529-8","article-title":"Etrolizumab in moderate-to-severe ulcerative colitis","volume":"384","author":"Armuzzi","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD011572.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"A778","DOI":"10.1016\/0016-5085(95)27423-5","article-title":"Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis","volume":"108","author":"Bayles","year":"1995","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD011572.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0016-5085(88)90569-0","article-title":"5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis","volume":"94","author":"Biddle","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Bossa F Annese V Valvano MR Latiano A Martino G Rossi L Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: A randomized, double-blind sham-controlled study Inflammatory Bowel Diseases 2013 1872 9","DOI":"10.1097\/MIB.0b013e3182874065"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Buckell NA Gould SR Day DW Lennard-Jones JE Edwards AM Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis Gut 1978 1140 3","DOI":"10.1136\/gut.19.12.1140"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2036.1990.tb00456.x","article-title":"The efficacy of tobramycin in the treatment of ulcerative colitis","volume":"4","author":"Burke","year":"1990","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0101|cit101","unstructured":"Calring L Kagevi I Anker-Hans\u00e9n O Hallerb\u00e4ck B Svedberg LE Wallin T Sucralfate enema in the treatment of ulcerative proctitis: A randomized placebo controlled double blind study Gut 1994 A119"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Campieri M Lanfranchi G A Bazzocehi G Brignola C Corazza G Cortini C Salicylate other than 5-aminosalicylic acid ineffective in ulcerative colitis Lancet 1978 993","DOI":"10.1016\/S0140-6736(78)92556-4"},{"issue":"4","key":"10.1002\/14651858.CD011572.pub2-BIB0103|cit103","first-page":"278","article-title":"Effect of 5-aminosalicylic acid in local treatment of active ulcerative colitis. A double blind multicentre trial","volume":"13","author":"Campieri","year":"1981","journal-title":"Italian Journal of Gastroenterology"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD011572.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.1007\/BF01312467","article-title":"Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis","volume":"32","author":"Campieri","year":"1987","journal-title":"Digestive Diseases & Sciences"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0105|cit105","first-page":"A58","article-title":"5-Aminosalicylic Acid, Sucralfate and Placebo Enemas in the Treatment of Distal Ulcerative Colitis (UC)","volume":"94","author":"Campieri","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0106|cit106","unstructured":"Campieri M Brunetti G Miglioli M Barbara L Russo A Aprile G Topical treatment with 5-ASA suppositories in distal ulcerative colitis. A randomized double blind placebo controlled study with Asacol suppositories. An Italian co-operative study group Italian Journal of Gastroenterology 1989 15 6"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0107|cit107","doi-asserted-by":"crossref","unstructured":"Campieri M Gionchetti P Belluzzi A Brignola C Tampieri M Iannone P Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial International Journal of Colorectal Disease 1990 79 81","DOI":"10.1007\/BF00298473"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"Campieri M Franchis R Bianchi Porro G Ranzi T Brunetti G Barbara L Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial Scandanavian Journal of Gastroenterology 1990 663 8","DOI":"10.3109\/00365529008997590"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0109|cit109","first-page":"41","article-title":"Sucralfate, 5-aminosalicylic acid and placebo enemas in the treatment of distal ulcerative colitis","volume":"3","author":"Campieri","year":"1991","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0110|cit110","unstructured":"Campieri M Bianchi P Bianchi P G d'Albasio G Capurso L Cottone M Comparison of 5-ASA (ASACOL\u00ae) enema and foam in the treatment of distal ulcerative colitis Italian Journal of Gastroenterology 1991 510 1"},{"issue":"4","key":"10.1002\/14651858.CD011572.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"A805","DOI":"10.1016\/0016-5085(95)27529-0","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: results at 12 months","volume":"108","author":"D'Albasio","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0112|cit112","unstructured":"D'Albasio G Pacini F Camarri E Messori A Trallori G Bonanomi A G Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study American Journal of Gastroenterology 1997 1143 7"},{"issue":"5","key":"10.1002\/14651858.CD011572.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1572-0241.1998.228_a.x","article-title":"Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group","volume":"93","author":"d'Albasio","year":"1998","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0114|cit114","unstructured":"D'Arienzo A Panarese A D'Armiento F P Lancia C Quattrone P Giannattasio F 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial American Journal of Gastroenterology 1990 1079 82"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.crohns.2009.09.007","article-title":"Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX 9 mg extended-release tablets in patients with active left-sided ulcerative colitis","volume":"4","author":"D'Haens","year":"2010","journal-title":"Journal of Crohn's & colitis"},{"issue":"1","key":"10.1002\/14651858.CD011572.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/00365529209011158","article-title":"A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis","volume":"27","author":"Danielsson","year":"1992","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"Supp 1","key":"10.1002\/14651858.CD011572.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/S1873-9946(14)60514-6","article-title":"Pooled clinical trial analysis of MMX mesalazine safety: Focus on 4.8 g\/d long-term exposure","volume":"8","author":"Silva Sanchez","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0118|cit118","doi-asserted-by":"crossref","unstructured":"Davies PS Rhodes J Heatley RV Owen E Metronidazole in the treatment of chronic proctitis: a controlled trial Gut 1977 680 1","DOI":"10.1136\/gut.18.8.680"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0119|cit119","doi-asserted-by":"crossref","unstructured":"Dew MJ Hughes P Harries AD Williams G Evans BK Rhodes J Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid BMJ 1982 1012","DOI":"10.1136\/bmj.285.6347.1012"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Dick AP Grayson MJ Carpenter RG Petrie A Controlled trial of sulphasalazine in the treatment of ulcerative colitis Gut 1964 437 42","DOI":"10.1136\/gut.5.5.437"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0121|cit121","doi-asserted-by":"crossref","unstructured":"Dickinson RJ O'Connor HJ Pinder I Hamilton I Johnston D Axon AT Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis Gut 1985 1380 4","DOI":"10.1136\/gut.26.12.1380"},{"issue":"12","key":"10.1002\/14651858.CD011572.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/gut.14.12.923","article-title":"A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin)","volume":"14","author":"Dissanayake","year":"1973","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"S647","DOI":"10.14309\/00000434-201210001-01601","article-title":"Adalimumab induction dose reduces the risk of hospitalizations and colectomies in patients with ulcerative colitis during the first 8 weeks of therapy","volume":"107","author":"Feagan","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0124|cit124","doi-asserted-by":"crossref","unstructured":"Feurle GE Theuer D Velasco S Barry BA W\u00f6rdehoff D Sommer A Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial Gut 1989 1354 61","DOI":"10.1136\/gut.30.10.1354"},{"issue":"6","key":"10.1002\/14651858.CD011572.pub2-BIB0125|cit125","first-page":"473","article-title":"On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon","volume":"27","author":"Fruehmorgen","year":"1980","journal-title":"Hepato-Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0126|cit126","first-page":"36","article-title":"The effectiveness of packaged salicylazosulfapyridine (Azulfidine)-enema in proctitis, proto-sigmoiditis and left-sided colitis [German]","volume":"19","author":"Fruhmorgen","year":"1981","journal-title":"Zeitschrift fur Gastroenterologie"},{"issue":"7","key":"10.1002\/14651858.CD011572.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/BF01296134","article-title":"4-Aminosalicyclic acid retention enemas in treatment of distal colitis","volume":"32","author":"Gandolfo","year":"1987","journal-title":"Digestive Diseases and Sciences"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD011572.pub2-BIB0128|cit128","first-page":"A1395","article-title":"Deterioration of Left Sided Ulcerative Colitis After Withdrawl of Sulfasalazine","volume":"88","author":"Ginsberg","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0129|cit129","doi-asserted-by":"crossref","unstructured":"Ginsberg AL Beck LS McIntosh TM Nochomovitz LE Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial Annals of Internal Medicine 1988 195 9","DOI":"10.7326\/0003-4819-108-2-195"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0130|cit130","doi-asserted-by":"crossref","unstructured":"Ginsberg AL Davis ND Nochomovitz LE Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid Gastroenterology 1992 448 52","DOI":"10.1016\/0016-5085(92)90089-H"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0131|cit131","unstructured":"Gionchetti P Rizzello F Ferrieri A Venturi A Brignola C Ferretti M Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial Digestive Diseases and Sciences 1999 1220 1"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD011572.pub2-BIB0132|cit132","first-page":"A195","article-title":"Randomized Clinical Trial of Mesalamine (5-ASA) Enemas in Distal Ulcerative Colitis: A Dose-Ranging Placebo Controlled Study","volume":"96","author":"Hanauer","year":"1989","journal-title":"Gastroenterology"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD011572.pub2-BIB0133|cit133","first-page":"A195","article-title":"Dose-Ranging Study of Oral Mesalamine Capsule (Pentasa) for Active Ulcerative Colitis","volume":"96","author":"Hanauer","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0134|cit134","unstructured":"Hanauer S Beshears L Wilkinson C Induction of Remission in a Dose-Ranging Study of Oral Mesalamine Capsules (Pentasa) Gastroenterology 1990 A174"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0135|cit135","first-page":"A634","article-title":"Placebo response in UC: analysis of a multi-center, double-blind trial of controlled- release mesalamine (Pentasa)","volume":"102","author":"Hanauer","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0136|cit136","first-page":"1188","article-title":"Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0137|cit137","first-page":"A696","article-title":"Maintenance of remission of ulcerative colitis by mesalamine (Asacol) vs. placebo","volume":"106","author":"Hanauer","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7326\/0003-4819-124-2-199601150-00003","article-title":"An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial","volume":"124","author":"Hanauer","year":"1996","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0139|cit139","first-page":"A921","article-title":"A multi-center, double-blind, placebo-controlled, dose-ranging trial of olsalazine for mild-moderately active ulcerative colitis","volume":"110","author":"Hanauer","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0140|cit140","doi-asserted-by":"crossref","unstructured":"Hanauer SB Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group Inflammatory Bowel Diseases 1998 79 83","DOI":"10.1097\/00054725-199805000-00001"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0016-5085(98)70131-3","article-title":"Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study","volume":"115","author":"Hanauer","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0142|cit142","first-page":"663","article-title":"MMX mesalamine for providing remission of active mild-to-moderate ulcerative","volume":"13","author":"Hanauer","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0143|cit143","first-page":"494","article-title":"MMX mesalamine for induction and maintenance therapy in mild-to-moderate ulcerative colitis","volume":"5","author":"Hanauer","year":"2009","journal-title":"Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0144|cit144","first-page":"A697","article-title":"Efficacy of zileuton, a 5-lipoxygenase inhibitor, in the maintenance of remission in patients with ulcerative colitis","volume":"106","author":"Hawkey","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1053\/gast.1997.v112.pm9041232","article-title":"A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis","volume":"112","author":"Hawkey","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.305.6844.20","article-title":"Randomised controlled trial of azathioprine withdrawal in ulcerative colitis","volume":"305","author":"Hawthorne","year":"1992","journal-title":"BMJ"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD011572.pub2-BIB0147|cit147","first-page":"A1418","article-title":"Azodisalicylate (ADS) in the Treatment of Ulcerative Colitis (UC): A Controlled Trial and Assessment of Drug Disposition","volume":"88","author":"Hetzel","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/00365528809101552","article-title":"Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition","volume":"148","author":"Hetzel","year":"1988","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0149|cit149","doi-asserted-by":"crossref","unstructured":"Hollanders D Thomson JM Schofield PF Tranexamic acid therapy in ulcerative colitis Postgraduate Medical Journal 1982 87 91","DOI":"10.1136\/pgmj.58.676.87"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0150|cit150","doi-asserted-by":"crossref","unstructured":"J\u00e4rnerot G Hertervig E Friis-Liby I Blomquist L Karl\u00e9n P Gr\u00e4nn\u00f6 C Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 2005 1805 11","DOI":"10.1053\/j.gastro.2005.03.003"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0151|cit151","doi-asserted-by":"crossref","unstructured":"Jewell DP Truelove SC Azathioprine in ulcerative colitis: an interim report on a controlled therapeutic trial British Medical Journal 1972 709 12","DOI":"10.1136\/bmj.1.5802.709"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/bmj.4.5945.627","article-title":"Azathioprine in ulcerative colitis: final report on controlled therapeutic trial","volume":"4","author":"Jewell","year":"1974","journal-title":"British Medical Journal"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011572.pub2-BIB0153|cit153","first-page":"126","article-title":"Safety analysis of MMX mesalazine for the maintenance of remission of mild-to-moderate ulcerative colitis: results of a 4-month interim data analysis","volume":"55","author":"Kamm","year":"2006","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0154|cit154","doi-asserted-by":"crossref","unstructured":"Kamm M A Lichtenstein G R Sandborn W J Schreiber S Lees K Barrett K Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis Gut 2008 893 902","DOI":"10.1136\/gut.2007.138248"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00054725-200912002-00100","article-title":"Induction of clinical and endoscopic remission in mild-to-moderate ulcerative colitis in patients treated with MMX mesalamine: Established versus newly diagnosed disease","volume":"15","author":"Kamm","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.20580","article-title":"Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis","volume":"15","author":"Kamm","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"issue":"7","key":"10.1002\/14651858.CD011572.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/ajg.2014.104","article-title":"First multicenter study of modified release phosphatidylcholine LT-02 in ulcerative colitis: A randomized, placebo-controlled trial in mesalazine-refractory courses","volume":"109","author":"Karner","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0158|cit158","doi-asserted-by":"crossref","unstructured":"Kirk AP Lennard-Jones JE Controlled trial of azathioprine in chronic ulcerative colitis British Medical Journal 1982 1291 2","DOI":"10.1136\/bmj.284.6325.1291"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0159|cit159","first-page":"A714","article-title":"Long-term results of oral cyclosporin in patients with severe ulcerative colitis: a double-blind, randomized, multi-center trial","volume":"106","author":"Kornbluth","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"A67","DOI":"10.1016\/S0016-5085(03)80331-1","article-title":"Multicenter, randomized, double-blind, placebo-controlled trial of deligoparin (ultra low molecular weight heparin) for active ulcerative colitis","volume":"124","author":"Korzenik","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0161|cit161","first-page":"No. 90","article-title":"Topical beclomethasone diproprionate for inflammatory bowel disease","volume":"14","author":"Kumana","year":"1981","journal-title":"Annals of the Royal College of Physicians and Surgeons of Canada"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0162|cit162","first-page":"827","article-title":"[4-ASA by oral administration in hemorrhagic rectocolitis: first controlled study]","volume":"16","author":"Lemann","year":"1992","journal-title":"Gastroenterologie Clinique et Biologique"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0163|cit163","doi-asserted-by":"crossref","unstructured":"Lennard-Jones J E Baron J H Connell A M Avery Jones F A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis Gut 1962 207","DOI":"10.1136\/gut.3.3.207"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0140-6736(65)90973-6","article-title":"Prednfeone as maintenance treatment for ulcerative colitis in remission","volume":"1","author":"Lennard-Jones","year":"1965","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0165|cit165","first-page":"3323","article-title":"An open-label trial of the PPAR ligand rosiglitazone for active ulcerative colitis","volume":"96","author":"Lewis","year":"2001","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/S1873-9946(13)60412-2","article-title":"Rates of \"patient-defined\" remission with adalimumab in patients with ulcerative colitis: Subanalysis of ULTRA 1 and ULTRA 2","volume":"7","author":"Lewis","year":"2013","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0167|cit167","first-page":"667","article-title":"MMX mesalamine induces remission of mild-to-moderate ulcerative colitis in patients who have changed directly from other oral 5-ASA therapies and in those who have not previously received or who have discontinued 5-ASA: A combined analysis of two phase III studies","volume":"13","author":"Lichtenstein","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0168|cit168","doi-asserted-by":"crossref","unstructured":"Lichtenstein G R Kamm M A Sandborn W J Lyne A Joseph R E MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations Alimentary Pharmacology and Therapeutics 2008 1094 102","DOI":"10.1111\/j.1365-2036.2008.03688.x"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0169|cit169","doi-asserted-by":"crossref","unstructured":"Lichtenstein G R Diamond R H Wagner C L Fasanmade A A Olson A D Marano C W Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials Alimentary Pharmacology and Therapeutics 2009 210 26","DOI":"10.1111\/j.1365-2036.2009.04027.x"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/00054725-200912002-00104","article-title":"Induction of mucosal healing in mild-to-moderate ulcerative colitis in patients treated with MMX mesalamine: Established versus newly diagnosed disease","volume":"15","author":"Lichtenstein","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0171|cit171","first-page":"S165","article-title":"Once-daily mesalamine granules (1.5g) for maintenance of remission from ulcerative colitis: A subgroup analysis","volume":"1)","author":"Lichtenstein","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0172|cit172","doi-asserted-by":"crossref","unstructured":"Lichtenstein G R Zakko S Gordon G L Murthy U Sedghi S Pruitt R Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials Alimentary Pharmacology and Therapeutics 2012 126 34","DOI":"10.1111\/j.1365-2036.2012.05142.x"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1016\/S0016-5085(13)60826-4","article-title":"Budesonide MMX 9 mg induces remission in mild-to-moderately active UC patients regardless of prior history of 5-ASA therapy","volume":"1)","author":"Lichtenstein","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/01.MIB.0000438826.05786.93","article-title":"Budesonide MMX versus placebo in patients with active, mild-to-moderate ulcerative colitis who were 5-ASA naive or previously treated with 5-ASA","volume":"19","author":"Lichtenstein","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0175|cit175","doi-asserted-by":"crossref","unstructured":"Lichtiger S Present D H Kornbluth A Gelernt I Bauer J Galler G Cyclosporine in severe ulcerative colitis refractory to steroid therapy New England Journal of Medicine 1994 1841 5","DOI":"10.1056\/NEJM199406303302601"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0176|cit176","unstructured":"Lindgren S Suhr O Persson T Pantzar N Treatment of active distal ulcerative colitis (UC) and maintenance of remission with Entocort\u00ae enema: A randomised controlled dosage study Gut 1997 A223"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(01)83727-6","article-title":"BUDESONIDE ENEMA ONCE DAILY SHOWS SIMILAR EFFICACY AS BUDESONIDE ENEMA TWICE DAILY FOR TREATMENT OF ACTIVE DISTAL ULCERATIVE COLITIS","volume":"120","author":"Lindgren","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0178|cit178","doi-asserted-by":"crossref","unstructured":"Lindgren S L\u00f6fberg R Bergholm L Hellblom M Carling L Ung K A Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis Scandanavian Journal of Gastroenterology 2002 705 10","DOI":"10.1080\/00365520212512"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0179|cit179","first-page":"231","article-title":"5-Aminosalicylic acid (5-ASA) enemas in the treatment of acute ulcerative colitis: A controlled study. [Portuguese]","volume":"96","author":"Lopes Pontes","year":"1988","journal-title":"Folha Medica"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"S514","DOI":"10.14309\/00000434-201310001-01707","article-title":"Comparative efficacy of adalimumab, golimumab, and infliximab in the treatment of patients with ulcerative colitis: An induction analysis","volume":"108","author":"Mallow","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0181|cit181","unstructured":"Marakhovski YKh Lakovich F S Prozetski V A Mrakhovski K I Azemsha E I Domorod A I Comparative, randomised study of the efficacy and tolerance of bosmofalk vs Placebo in patients with active ulcerative colitis Gastroenterology 1999 A132"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/gut.42.2.195","article-title":"Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: A randomised double blind placebo controlled multicentre study","volume":"42","author":"Marteau","year":"1998","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0183|cit183","first-page":"A229","article-title":"Effect of hydroxychloroquine in the treatment of active ulcerative colitis: a double blind controlled trial","volume":"100","author":"Mayer","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0184|cit184","first-page":"A231","article-title":"Multicenter trial of Pentasa for active ulcerative colitis","volume":"100","author":"Miner","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0185|cit185","first-page":"A666","article-title":"Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa)","volume":"102","author":"Miner","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0186|cit186","unstructured":"Miner P Daly R Nester T Group and the Rowasa Study The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis Gastroenterology 1994 A736"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF02065413","article-title":"Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group","volume":"40","author":"Miner","year":"1995","journal-title":"Digestive Diseases & Sciences"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0188|cit188","first-page":"199","article-title":"Local treatment of ulcerative proctitis with salicylazosulphapyridine (Salazopyrin) enema","volume":"15","author":"Moller","year":"1978","journal-title":"Clinical Trials Journal"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0189|cit189","first-page":"A431","article-title":"A phase II placebo-controlled, randomized, multicenter study to evaluate efficacy and safety of interferon beta-1a in patients with ulcerative colitis","volume":"122","author":"Musch","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0190|cit190","unstructured":"Musch E Raedler A Andus T Kruis W Schreiber S Lorenz A Results of a randomised, double-blind, placebo-controlled, multi-centre, phase-II study to test the effectivity and tolerance of Interferon-beta-1a (CHO-beta) [rIFN-beta-1a] in patients with ulcerative colitis Zeitschrift fur Gastroenterologie 2002 705"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1542-3565(05)00208-9","article-title":"Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial","volume":"3","author":"Musch","year":"2005","journal-title":"Clinical Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0192|cit192","unstructured":"Ng\u00f4 Y G\u00e9linet J M Ivanovic A Kac J Sch\u00e9nowitz G Vilotte J Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial Gastroent\u00e9rologie Clinique et Biologique 1992 782 6"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(01)82251-4","article-title":"Recombinant human interferon-beta (IFNb-1A) induces remission and is well tolerated in moderately active ulcerative colitis (UC)","volume":"120","author":"Nikolaus","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0194|cit194","unstructured":"Onuk MD Kaymakoglu S Demir K \u00c7akaloglu Y Baztas G Mungan Z Low-dose weekly methotrexate therapy in remission maintenance in ulcerative colitis Gut 1996 A75"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1365-2036.2011.04620.x","article-title":"Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question","volume":"33","author":"Orchard","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0196|cit196","doi-asserted-by":"crossref","unstructured":"Palmer K R Goepel J R Holdsworth C D Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial British Medical Journal 1981 1571 3","DOI":"10.1136\/bmj.282.6276.1571"},{"issue":"8","key":"10.1002\/14651858.CD011572.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2036.2008.03757.x","article-title":"Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis","volume":"25","author":"Pastorelli","year":"2008","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0198|cit198","first-page":"334","article-title":"Rosiglitazone for active ulcerative colitis: A randomized placebo-controlled trial","volume":"15","author":"Piche","year":"2008","journal-title":"H\u00e9pato-Gastro and Oncologie Digestive"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1046\/j.1365-2036.2000.00784.x","article-title":"Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: A double-blind, randomized, placebo-controlled study","volume":"14","author":"Pokrotnieks","year":"2000","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(08)62301-X","article-title":"Infliximab treatment for ulcerative colitis: clinical response, clinical remission and mucosal healing in patients with moderate or severe disease in the Active Ulcerative Colitis Trials (ACT1 and ACT2)","volume":"134","author":"Present","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(08)62307-0","article-title":"Safety and tolerability of twice-daily balsalaside tablets: results of a phase 3, randomized, double-blind, placebo-controlled, multicenter study","volume":"134","author":"Pruitt","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0202|cit202","first-page":"A765","article-title":"Double-blind controlled trial of bismuth-carbomer and 5-aminosalicylcic acid (5-ASA) enemas in distal ulcerative colitis","volume":"104","author":"Pullan","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"A139","DOI":"10.1136\/gut.2011.239301.295","article-title":"52-week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and\/or immunosuppressants","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ibd.21697","article-title":"Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies","volume":"18","author":"Reinisch","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/01.MIB.0000438819.81129.12","article-title":"Association between week 8 mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA1 and ULTRA2","volume":"19","author":"Reinisch","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1873-9946(14)60010-6","article-title":"Long-term safety and efficacy of golimumab in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT-SC Maintenance study extension","volume":"8","author":"Reinisch","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/S1873-9946(14)60672-3","article-title":"Association between Week 8 Mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2","volume":"8","author":"Reinisch","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"issue":"5 Part 2","key":"10.1002\/14651858.CD011572.pub2-BIB0208|cit208","first-page":"A381","article-title":"Olsalazine in the treatment of mild to moderate ulcerative colitis","volume":"94","author":"Robinson","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0016-5085(19)32641-1","article-title":"A controlled trial of azathioprine in the management of chronic ulcerative colitis","volume":"69","author":"Rosenberg","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0210|cit210","first-page":"593","article-title":"Phase 3 study to evaluate the SC golimumab maintenance therapy in moderate to severe UC: Pursuit-maintenance","volume":"28","author":"Rutgeerts","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0211|cit211","first-page":"591","article-title":"Phase 2\/3 randomized, placebo-controlled, double-blind study of SC golimumab induction in moderate to Severe UC","volume":"28","author":"Rutgeerts","year":"2013","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0016-5085(09)60290-0","article-title":"A placebo-controlled trial of visilizumab in patients with intravenous (IV) steroid refractory ulcerative colitis (UC)","volume":"136","author":"Sandborn","year":"2009","journal-title":"Gastroentrology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.14309\/00000434-201010001-01180","article-title":"Randomized, double-blind, placebo-controlled trial of andrographis paniculata extract (HMPL-004) in patients with moderately active Crohn's disease","volume":"105","author":"Sandborn","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0214|cit214","doi-asserted-by":"crossref","unstructured":"Sandborn WJ Colombel JF Frankel M Hommes D Lowder JN Mayer L Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis Gut 2010 1485 92","DOI":"10.1136\/gut.2009.205443"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.14309\/00000434-201110002-01274","article-title":"Induction of clinical and endoscopic remission of mild to moderately active ulcerative colitis with budesonide MMX 9 mg: Analysis of pooled data from two phase 3 studies","volume":"106","author":"Sandborn","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2036.2011.04800.x","article-title":"Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis - Additional results from two controlled studies","volume":"34","author":"Sandborn","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0217|cit217","doi-asserted-by":"crossref","unstructured":"Sandborn WJ Assche G Reinisch W Colombel JF D'Haens G Wolf DC Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 2012 257 65","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1016\/S0016-5085(13)60825-2","article-title":"Efficacy of budesonide MMX in reduction of symptoms in patients with mild-to-moderately active ulcerative colitis: A pooled analysis of the core I and core II studies","volume":"1)","author":"Sandborn","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0219|cit219","doi-asserted-by":"crossref","unstructured":"Sandborn WJ Targan SR Byers VS Rutty DA Mu H Zhang X Andrographis paniculata extract (HMPL-004) for active ulcerative colitis American Journal of Gastroenterology 2013 90 8","DOI":"10.1038\/ajg.2012.340"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflammatory Bowel Diseases"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study","volume":"7","author":"Sands","year":"2001","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.14309\/00000434-201410002-01618","article-title":"Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease","volume":"109","author":"Sands","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD011572.pub2-BIB0223|cit223","first-page":"132","article-title":"MMX mesalazine, a novel formulation of 5-ASA given once or twice daily, is well tolerated in patients with active mild-to-moderate ulcerative colitis: an analysis of adverse events in combined data from three randomised studies","volume":"55","author":"Schreiber","year":"2006","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0224|cit224","doi-asserted-by":"crossref","unstructured":"Schreiber S Maintenance of remission in patients with ulcerative colitis with once- or twice-daily MMX mesalazine: results of an international multicentre randomised trial Zeitschrift f\u00fcr Gastroenterologie 2008 944","DOI":"10.1055\/s-0028-1089403"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0225|cit225","doi-asserted-by":"crossref","unstructured":"Schreiber S The efficacy of MMX mesalazine as the sole medication for the induction and maintenance of remission in patients with mild-to-moderate ulcerative colitis treated over 14-16 months Zeitschrift f\u00fcr Gastroenterologie 2008 943 4","DOI":"10.1055\/s-0028-1089402"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0226|cit226","unstructured":"Schulz U Hanke P Seige K Rectal effect of salazopyrine in ulcerative colitis during a double-blind study Wiener Zeitschrift fur Innere Medizin und Ihre Grenzgebiete 1973 185 9"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/bmj.291.6506.1373","article-title":"Olsalazine in active ulcerative colitis","volume":"291","author":"Selby","year":"1985","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0228|cit228","first-page":"A90","article-title":"Evaluating induction and maintenance treatment with MMX mesalazine for patients with mild-to-moderate ulcerative colitis","volume":"25","author":"Solomon","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00054725-201112002-00080","article-title":"Pooled safety analysis of long-term MMXVR, a mesalamine administration","volume":"17","author":"Solomon","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/S1873-9946(12)60372-9","article-title":"MMX, a mesalazine and long-term safety: a pooled analysis","volume":"6","author":"Solomon","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0231|cit231","first-page":"S62","article-title":"Exposure-response analyses to support dose selection of BMS-936557, a monoclonal antibody to IP-10, for a phase 2b study in patients with ulcerative colitis","volume":"89","author":"Tao","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"A62","DOI":"10.1016\/S0016-5085(03)80305-0","article-title":"A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis","volume":"124","author":"Tilg","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0233|cit233","first-page":"361","article-title":"A trial of hydroxychloroquine administration in the treatment of exacerbated ulcerative colitis","volume":"73","author":"Tomecki","year":"1985","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0234|cit234","first-page":"78","article-title":"Tacrolimus in refractory ulcerative rectocolitis treatment to a steroid therapy: A randomized study versus placebo","volume":"14","author":"Touchefeu","year":"2007","journal-title":"H\u00e9pato-Gastro & Oncologie Digestive"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/01.MIB.0000172807.26748.16","article-title":"RDP58 is a novel and potentially effective oral therapy for ulcerative colitis","volume":"11","author":"Travis","year":"2005","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/00054725-201112002-00066","article-title":"Induction of remission with oral budesonide MMXVR (9 mg) tablets in patients with mild to moderate, active Ulcerative Colitis: A multicenter, open-label efficacy and safety study","volume":"17","author":"Travis","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S1873-9946(12)60182-2","article-title":"Induction of clinical and endoscopic remission with budesonide MMX in mild to moderately active ulcerative colitis: Pooled data from two phase 3 studies","volume":"6","author":"Travis","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis. Final report on a therapeutic trial","volume":"4947","author":"Truelove","year":"1955","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0239|cit239","doi-asserted-by":"crossref","unstructured":"Truelove SC Hambling MH Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium: a report on a controlled therapeutic trial British Medical Journal 1958 1072 7","DOI":"10.1136\/bmj.2.5104.1072"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0240|cit240","doi-asserted-by":"crossref","unstructured":"Truelove SC Systemic and local corticosteroid therapy in ulcerative colitis British Medical Journal 1960 464 7","DOI":"10.1136\/bmj.1.5171.464"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/gut.21.7.632","article-title":"Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulphasalazine","volume":"21","author":"Hees","year":"1980","journal-title":"Gut"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0242|cit242","doi-asserted-by":"crossref","unstructured":"Watkinson G Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium: a controlled trial employing restricted sequential analysis British Medical Journal 1958 1077 82","DOI":"10.1136\/bmj.2.5104.1077"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0243|cit243","doi-asserted-by":"crossref","unstructured":"Wright JP O'Keefe EA Cumming L Jaskiewicz K Olsalazine in maintenance of clinical remission in patients with ulcerative colitis Digestive Diseases and Sciences 1993 1837 42","DOI":"10.1007\/BF01296107"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0244|cit244","first-page":"A521","article-title":"Once-daily mesalamine granules effectively maintain remission from ulcerative colitis: Data from 2 phase 3 trials","volume":"1)","author":"Zakko","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0245|cit245","unstructured":"Zinberg J Molinas S Das KM Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis American Journal of Gastroenterology 1990 562 6"},{"issue":"11","key":"10.1002\/14651858.CD011572.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ecco-jcc\/jjw103","article-title":"Clinical effects of a topically applied toll-like receptor 9 agonist in active moderate-to-severe ulcerative colitis","volume":"10","author":"Atreya","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"6","key":"10.1002\/14651858.CD011572.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/ecco-jcc\/jjw036","article-title":"AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial","volume":"10","author":"Harris","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/MIB.0000000000001000","article-title":"Tripeptide K(D)PT Is well tolerated in mild-to-moderate ulcerative colitis: results from a randomized multicenter study","volume":"23","author":"Kucharzik","year":"2017","journal-title":"Inflammatory Bowel Diseases"},{"issue":"7","key":"10.1002\/14651858.CD011572.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ecco-jcc\/jjv208","article-title":"Twice-daily budesonide 2-mg foam induces complete mucosal healing in patients with distal ulcerative colitis","volume":"10","author":"Naganuma","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"4","key":"10.1002\/14651858.CD011572.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ecco-jcc\/jjv224","article-title":"Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: a randomised, placebo-controlled, phase 2b study","volume":"10","author":"Sandborn","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"issue":"18","key":"10.1002\/14651858.CD011572.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"Supp 1","key":"10.1002\/14651858.CD011572.pub2-BIB0252|cit252","first-page":"S157","article-title":"Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials","volume":"4","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/apt.13653","article-title":"Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis","volume":"44","author":"Sandborn","year":"2016","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"Supp 1","key":"10.1002\/14651858.CD011572.pub2-BIB0254|cit254","first-page":"S39","article-title":"Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis","volume":"10","author":"Assche","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ctim.2013.01.002","article-title":"Trial designs and exploration of the placebo response","volume":"21","author":"Dieppe","year":"2013","journal-title":"Complementary Therapies in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"7109","key":"10.1002\/14651858.CD011572.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD011572.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3923","article-title":"The placebo response in medicine: minimize, maximize or personalize?","volume":"12","author":"Enck","year":"2013","journal-title":"Nature Reviews Drug Discovery"},{"issue":"11","key":"10.1002\/14651858.CD011572.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0260|cit260","article-title":"Chapter 7: Selecting studies and collecting data","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0261|cit261","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from www.cochrane-handbook.org"},{"issue":"5","key":"10.1002\/14651858.CD011572.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ecco-jcc\/jjw004","article-title":"Systematic review and meta-analysis: placebo rates in induction and maintenance trials of ulcerative colitis","volume":"10","author":"Jairath","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2009.01.029","article-title":"Meta-analysis of the placebo response in antidepressant trials","volume":"118","author":"Rief","year":"2009","journal-title":"Journal of Affective Disorders"},{"key":"10.1002\/14651858.CD011572.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0076-6879(04)83017-9","article-title":"Bayesian methods to improve sample size approximations","volume":"383","author":"Schmid","year":"2004","journal-title":"Methods in Enzymology"},{"issue":"29","key":"10.1002\/14651858.CD011572.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011572.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1053\/j.gastro.2006.12.037","article-title":"A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis","volume":"132","author":"Su","year":"2007","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD011572.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Statistics in Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011572.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T01:50:24Z","timestamp":1683942624000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011572.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":267,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011572.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,8]]}}}